

23 November 2023

## CANCER TREATMENTS

I would be very grateful if you could please answer these questions in relation to cancer treatment.

**1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases?**

**A) Metastatic Melanoma:**

14 - Melanoma (Metastatic/Adjuvant detail not available)

**B) Adjuvant Melanoma:**

see answer above

**C) BRAF mutated Lung Cancer:**

<5

**2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases?**

**A) Metastatic Melanoma:**

28 – Melanoma (Metastatic/Adjuvant etc detail not available)

**B) Colorectal Cancer:**

<5

**C) Any other indications:**

<5

*We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.*

*This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.*

*Disclosure would constitute a breach of the principles of the Data Protection Act 2018.*